ArticleScience signaling2025
Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors.
Abstract read
In one paragraph
Article in Science signaling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Dissecting cancer in a non-mammalian model: genomic insights from lemon frost geckos.BMC biology · 2026Article
- Suppression of AKT Activation Through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck Cancers.Molecular cancer therapeutics · 2026Article
- Fundamentals and emerging frontiers in p53-targeted drug development.Biochemistry and biophysics reports · 2026Review
- c-Myc regulated long noncoding RNA TRD-AS1 to affect the progression of oral squamous cell carcinoma.Genes & genomics · 2026Article
- Article
- Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL).Cancer biology & therapy · 2025Article
- Discovery of potent and selective PROTACs for the protein kinase LZK for the treatment of head and neck cancer.The Journal of biological chemistry · 2025Article
- Advancing Head and Neck Cancer Therapies: From Conventional Treatments to Emerging Strategies.Biomedicines · 2025Review
- Defeating kinases that promote tumorigenesis through non-catalytic functions with PROTACs - PIM kinase as an example.Expert opinion on therapeutic targetsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Amy L FunkLaboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, MD 21702, USA.ORCID 0000-0001-8272-5715
Meghri KaterjiLaboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, MD 21702, USA.ORCID 0009-0006-2263-9544
Marwa AfifiLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-4255, USA.ORCID 0000-0002-4877-7447
Katherine NyswanerLaboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, MD 21702, USA.
Carolyn C WoodroofeChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, NIH, Rockville, MD 20850, USA.
Zoe C EdwardsCell Division Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.ORCID 0000-0002-9232-9131
Eric LindbergChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, NIH, Rockville, MD 20850, USA.ORCID 0000-0002-4258-5583
Knickole L BergmanLaboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, MD 21702, USA.ORCID 0000-0002-1062-0671
Nancy R GoughBioSerendipity, LLC, Elkridge, MD 21075, USA.ORCID 0000-0001-5179-8890
Maxine R RubinLaboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, MD 21702, USA.ORCID 0009-0007-0031-528X
Kamila KarpińskaLaboratory of Molecular OncoSignalling, IMol Polish Academy of Sciences, Warsaw, Poland.ORCID 0000-0002-7349-5038
Eleanor W TrotterCell Division Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.
Sweta DashLaboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, MD 21702, USA.
Amy L RiesLaboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Amy JamesLaboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0002-7669-9220
Christina M RobinsonLaboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Simone DifilippantonioLaboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Baktiar O KarimMolecular Histopathology Laboratory, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0001-9604-9762
Ting-Chia ChangMolecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0001-6296-5797
Li ChenMolecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0001-7973-5912
Xin XuDivision of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Rockville, MD 20850, USA.ORCID 0000-0003-1163-9304
James H DoroshowDivision of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Rockville, MD 20850, USA.
Ivan AhelSir William Dunn School of Pathology, Oxford OX1 3RE, UK.ORCID 0000-0002-9446-3756
Anna A MarusiakLaboratory of Molecular OncoSignalling, IMol Polish Academy of Sciences, Warsaw, Poland.ORCID 0000-0001-8907-3131
Rolf E SwensonChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, NIH, Rockville, MD 20850, USA.ORCID 0000-0001-7804-7202
Steven D CappellLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-4255, USA.ORCID 0000-0002-2885-7327
John BrognardLaboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, MD 21702, USA.ORCID 0000-0002-9243-6615
Funding
Oncogenic Kinases in CancerZIABC011691 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BROGNARD, JOHN · 2016 to 2025
$14.4MIntramural NIH HHS ZIA BC011691NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003I
Abstract
The worldwide annual frequency and lethality of head and neck squamous cell carcinoma (HNSCC) is not improving, and thus, new therapeutic approaches are needed. Approximately 70% of HNSCC cases have either amplification or overexpression of
Indexed as
Gain of Function MutationHead and Neck NeoplasmsMAP Kinase Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins c-mycSquamous Cell Carcinoma of Head and NeckTumor Suppressor Protein p53AnimalsCell Line, TumorCell ProliferationHumansMiceMice, NudeProteolysisXenograft Model Antitumor AssaysMAP Kinase Kinase KinasesMYC protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-mycTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.